Go to content
DSM B.V.

DSM B.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 21 dec 2010 - 07:44
Statutaire naam DSM B.V.
Titel DSM to acquire Martek to add new Nutrition growth platform
Bericht DSM (NYSE Euronext: DSM KON) to offer US$31.50 for each share of Martek Biosciences Corporation (NASDAQ: MATK) in an all-cash transaction (through a tender offer) Total consideration of US$1,087 million (about EUR829 million) Offer price represents 35% premium to Martek`s closing share price on December 20, 2010 Martek Board of Directors recommends the offer Acquisition adds new growth platform for natural, healthy Polyunsaturated Fatty Acids (PUFAs) nutrition ingredients (Omega-3 DHA and Omega-6 ARA) PUFAs are clinically proven to have important human health benefits. Martek is a leader in this field with strong positions, especially in Infant Formula Nutrition applications